TRCT
NERV icon

Tower Research Capital (TRC)’s Minerva Neurosciences NERV Stock Holding History

Tower Research Capital (TRC)’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-501
Closed -$2.01K – 5403
2025
Q4 		$2.01K Sell
501
-840
-63% -$3.12K ﹤0.01% 4597
2025
Q3 		$2.82K Sell
1,341
-874
-39% -$1.79K ﹤0.01% 4578
2025
Q2 		$3.81K Sell
2,215
-428
-16% -$699 ﹤0.01% 4432
2025
Q1 		$4.49K Buy
2,643
+1,201
+83% +$2.37K ﹤0.01% 4250
2024
Q4 		$3.2K Sell
1,442
-466
-24% -$1.1K ﹤0.01% 4692
2024
Q3 		$5.09K Sell
1,908
-540
-22% -$1.57K ﹤0.01% 4330
2024
Q2 		$7.81K Sell
2,448
-1,655
-40% -$4.48K ﹤0.01% 4424
2024
Q1 		$10.6K Buy
4,103
+2,743
+202% +$16.8K ﹤0.01% 3680
2023
Q4 		$8.36K Sell
1,360
-1,378
-50% -$7.88K ﹤0.01% 4516
2023
Q3 		$18.9K Buy
2,738
+1,484
+118% +$13.3K ﹤0.01% 3430
2023
Q2 		$11.5K Buy
1,254
+432
+53% +$2.28K ﹤0.01% 3973
2023
Q1 		$1K Buy
+822
New +$1.7K ﹤0.01% 5582
2022
Q3 		– Sell
-3,995
Closed -$13K – 6336
2022
Q2 		$13K Buy
3,995
+3,448
+630% +$14.1K ﹤0.01% 4220
2022
Q1 		$4K Sell
547
-459
-46% -$2.82K ﹤0.01% 5228
2021
Q4 		$6K Buy
+1,006
New +$9.47K ﹤0.01% 5043
2021
Q3 		– Sell
-2,175
Closed -$40K – 6027
2021
Q2 		$40K Buy
2,175
+820
+61% +$17.7K ﹤0.01% 3211
2021
Q1 		$31K Sell
1,355
-427
-24% -$10.7K ﹤0.01% 3541
2020
Q4 		$33K Sell
1,782
-2,839
-61% -$71.5K ﹤0.01% 3492
2020
Q3 		$118K Buy
4,621
+3,763
+439% +$102K ﹤0.01% 3025
2020
Q2 		$25K Buy
858
+573
+201% +$33.6K ﹤0.01% 3565
2020
Q1 		$14K Sell
285
-110
-28% -$6.64K ﹤0.01% 1879
2019
Q4 		$22K Buy
395
+135
+52% +$5.95K ﹤0.01% 1863
2019
Q3 		$16K Buy
+260
New +$14.7K ﹤0.01% 2620
2019
Q2 		– Sell
-310
Closed -$19K – 4076
2019
Q1 		$19K Sell
310
-342
-52% -$20.6K ﹤0.01% 2296
2018
Q4 		$35K Buy
+652
New +$47.7K ﹤0.01% 1534
2018
Q3 		– Sell
-558
Closed -$37K – 4090
2018
Q2 		$37K Buy
558
+517
+1,261% +$31.4K ﹤0.01% 2039
2018
Q1 		$2K Buy
+41
New +$1.97K ﹤0.01% 2954
2017
Q3 		– Sell
-735
Closed -$52K – 4030
2017
Q2 		$52K Sell
735
-5
-0.7% -$324 0.01% 733
2017
Q1 		$48K Buy
740
+455
+160% +$35.3K ﹤0.01% 752
2016
Q4 		$27K Buy
+285
New +$29.1K ﹤0.01% 1881
2016
Q3 		– Sell
-25
Closed -$2K – 4161
2016
Q2 		$2K Sell
25
-63
-72% -$4K ﹤0.01% 3927
2016
Q1 		$4K Sell
88
-20
-19% -$854 ﹤0.01% 2908
2015
Q4 		$6K Sell
108
-359
-77% -$15K ﹤0.01% 2788
2015
Q3 		$19K Buy
467
+400
+597% +$18.4K ﹤0.01% 1774
2015
Q2 		$3K Sell
67
-22
-25% -$939 ﹤0.01% 3563
2015
Q1 		$3K Sell
89
-140
-61% -$5.8K ﹤0.01% 3584
2014
Q4 		$11K Buy
229
+100
+78% +$3.82K ﹤0.01% 2072
2014
Q3 		$6K Buy
+129
New +$6.86K ﹤0.01% 3170

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM

Tower Research Capital (TRC)'s NERV Position: Q1 2026 in Review

Tower Research Capital (TRC) sold out of Minerva Neurosciences (NERV) in Q1 2026, closing a stake of 501 shares — an estimated $2.01K sold.

Tower Research Capital (TRC) first reported a position in NERV in Q3 2014 and held it in 38 quarters. The position peaked at $118K in Q3 2020. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

  • Tower Research Capital (TRC) reported no remaining Minerva Neurosciences position as of Q1 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 501 Minerva Neurosciences shares in Q1 2026, an estimated $2.01K.
  • Tower Research Capital (TRC) first reported a position in Minerva Neurosciences in Q3 2014 and held it in 38 quarters.
  • Tower Research Capital (TRC)'s Minerva Neurosciences position peaked at $118K in Q3 2020.
  • 47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.